The cell-free fetal DNA (cffDNA) test is a new technology being used to assess the risk of a pregnant woman’s developing baby (fetus) against any abnormalities such as chromosome disorder like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) or Patau syndrome (trisomy 13). The global cell-free fetal DNA testing market is segmented on the basis of test types and geography. This new technology is being used as an alternative to currently available prenatal tests. It may be used to identify other rare conditions resulting from an extra chromosome or missing piece of chromosome (microdeletion).
Fetal DNA is found in mother’s blood stream, cell-free fetal DNA enters into the blood stream through the placenta, placenta is a flattened organ in the uterus where maternal blood and fetal blood. The fetal DNA can be split into very acute fragments, less than 200 base pairs on an average. Maternal DNA fragments are also present in the blood. Fetal DNA is first noticed after 22-25 days of fertilization and its concentrations increase as the time period of pregnancy increases. Diagnostic tests for pregnancy using fetal DNA is possible in seventh week of pregnancy. Fetal DNA can be rarely distinguished from the maternal DNA through diagnostic practice. Amniocentesis and chorionic villus sampling prenatal test is possible within 14-20 weeks and 10-13 weeks of pregnancy respectively. Cell-free fetal DNA non-invasive test is used to detect aneuploidy syndromes, fetal Down syndrome and signals a major shift in diagnostic practice and prenatal screening. The primary factor for the growth of global cell-free fetal DNA testing industry is growing awareness in the people and requirement of safe or low risk obstetric procedures for prenatal testing. The technology which is used in cell-free DNA analysis and its application to prenatal screening for aneuploidy is rapidly changing. The growth of cell-free fetal DNA testing market is primarily attributed to accurate and effective results for aneuploidy screening. Major factor which limits the growth of the global cell-free fetal DNA testing market is high cost of cell-free fetal DNA tests. The cell-free fetal DNA testing enables the parents to get information about general survivable fetal aneuploidies with a high accuracy and without any diagnostic procedure risk. In comparison with other screening method of aneuploidy, cell-free fetal DNA testing offers various advantages such as lower false-positive results of cell-free fetal DNA test as compared to other screening method. Aneuploidy is an unusual number of chromosomes, typically characterized by the absence of one copy of a single chromosome or by the increase in the amount of chromosomes. The presence of an extra copy of chromosome 21 is called trisomy 21, which causes Down syndrome. On the basis of test types, the global cell-free fetal DNA testing industry is segmented into detection of abnormal chromosome number, paternally inherited disorders, gender testing and so on. Get a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/cell-free-fetal-dna-cffdna-testing-market/request-sample On the basis of geography, the global cell-free fetal DNA testing market is segmented into North America, Europe, Asia Pacific, Japan, Latin America and Middle East & Africa. North America held largest share in the global market of cellfree fetal DNA testing followed by Europe, Japan and Asia Pacific owing to high occurrence of several diseases and increasing number of aneuploidies, great advancement in field of aneuploidy screening and developed healthcare infrastructure. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the global cell-free fetal DNA testing market, due to its quick and accurate result without any risk to developing fetus. The key players of global cell-free fetal DNA testing market are IIIumina Inc., Sequenom Laboratories, Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre, Apollo Path Labs, Agilent Technology, Biodesix Inc., Allenex AB, Biocept Inc., CareD Inc., Guardant Health Inc., Inivated Limited, Natera Inc., Quest Diagnostics, Roche Holdings AG, Sequenom Inc. and Trovagene Inc.
This report studies Cell-Free Fetal DNA Testing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering • Sequenom Laboratories • Illumina • Ariosa Diagnostics • Arup Laboratories • The Fetal Medicine Center • Apollo Path labs Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Cell-Free Fetal DNA Testing in these regions, from 2011 to 2021 (forecast), like • North America • Europe • China • Japan • Southeast Asia • India See More Reports of This Category by Million Insights @ https://www.millioninsights.com/industry/biotechnology Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into • Detection of Abnormal Chromosome Number • Gender Testing • Paternally Inherited Disorders